Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for mTOR Pathway and Tuberous Sclerosis Research.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for TSC1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TSC1 Recombinant Protein / Mutant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Mammalian cell expressed for native phosphorylation states. |
View TSC1 Products |
| Gene Delivery | TSC1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and rescue assays. |
View TSC1 Products |
| Benchmark Ab | Anti-TSC1 Recombinant Antibody High-affinity clone for western blot, immunoprecipitation, and IHC validation. |
View TSC1 Products |
| Validator | TSC1 siRNA Set Target-specific knockdown verification in disease models. |
View TSC1 Products |
| Related Target A | TSC2 (Tuberin) Obligate heterodimer partner of TSC1; critical for GAP activity towards RHEB. |
View TSC2 Products |
| Related Target B | RHEB Direct downstream target of the TSC1/TSC2 complex; key activator of mTORC1. |
View RHEB Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting the TSC1/TSC2 complex in vitro | Co-expression compatible recombinant TSC1 and TSC2 proteins with verified sequence integrity and high purity (>95%) |
| Evaluating phosphorylation-dependent regulation | HEK293 expressed TSC1 preserving native post-translational modifications (PTMs) |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included |
| False Positives in Phenotypic Screens | Validated siRNA included for specificity and target-knockdown checks |
Live Hamartin/TSC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the Hamartin/TSC1 pathway is undergoing a significant transition. Historically viewed as an undruggable tumor suppressor, TSC1 loss-of-function mutations drive hyperactivation of the mTORC1 pathway, causing Tuberous Sclerosis Complex (TSC), lymphangioleiomyomatosis (LAM), and various focal malignancies (e.g., bladder cancer). While downstream mTORC1 inhibitors (rapalogs) remain the standard of care, resistance and systemic toxicities limit their long-term efficacy.
The next wave of R&D is focusing on two frontlines: gene replacement therapies (using viral vectors to restore TSC1 function) and synthetic lethality screens to identify targetable vulnerabilities unique to TSC1-deficient cells. Consequently, robust cell-based assays and highly purified protein complexes are crucial for screening small molecules that selectively target downstream effectors or bypass pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy / mRNA | Academic Medical Centers, Biotech Startups | Tuberous Sclerosis Complex, LAM | Rescue Expression assays (Need high-titer Lentivirus for stable transfection) |
| Small Molecule (Synthetic Lethality) | Novartis, Oncology-focused Biotechs | TSC1-mutated Bladder & Renal Cancers | Target validation & phenotypic screening (Need validated siRNA and TSC1/TSC2 proteins) |
| mTORC1 Inhibitors (Combination) | Pfizer, AstraZeneca | Refractory Solid Tumors | Pathway readout validation (Need high-purity TSC1/TSC2 complex controls) |